Status:

UNKNOWN

Acquisition of Portal Venous CTCs and Exosomes From Patients With Pancreatic Cancer by EUS

Lead Sponsor:

Ying Lv

Conditions:

Pancreatic Cancer

Eligibility:

All Genders

18-80 years

Brief Summary

The investigators are going to explore the diagnostic and prognostic value of circulating tumor cells and exosomes extracted from the portal venous blood obtained with endoscopic ultrasound in pancrea...

Detailed Description

As the prognosis of pancreatic cancer, a kind of malignant tumor, remains poor due to the low diagnostic rate at the early stage, there is still a significant clinical need to determine individualized...

Eligibility Criteria

Inclusion

  • Aged from 18 to 80 years-old
  • Suspected pancreatic masses and referred for EUS-FNA for pathology diagnosis
  • Written informed consent

Exclusion

  • Patients who have received adjuvant chemotherapy and other anti-tumor treatments
  • Severe heart, lung, liver, kidney insufficiency, or severe bleeding disorders, severe coagulopathy or local/systemic infections, other critical illnesses
  • Women who are planning to become pregnant or are pregnant or breast-feeding

Key Trial Info

Start Date :

August 1 2018

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 1 2020

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT03821909

Start Date

August 1 2018

End Date

September 1 2020

Last Update

January 31 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Nanjing Drum Tower Hospital the Affiliated Hospital of Nanjing University Medical School

Nanjing, Jiangsu, China, 210008